PUBLICATIONS

Journal Articles
1. Ganyu G., Smith L., Liu A., and Lu. S-E. (2011) A genetic and biochemical map for the biosynthesis of occidiofungin, an antifungal produced by Burkholderia contaminans strain MS14, Applied and Environmental Microbiology. 77(17), 6189-6198 (2011)

2. Smith, L., What Have We Learned from Antibiotics? Current Pharmaceutical Biotechnology, 12(8), 1183 (2011).

3. Wilson-Stanford, S, and Smith, L., Commercial development and application of type a lantibiotics, Recent Pat Antiinfect Drug Discov. 6(2), 175-185 (2011).

4. Neeti, D., Noel, C, Ellis, D., Lu, S-E., Smith, J. L., Optimization of the Production of the Lantibiotic Mutacin 1140 in Modified M9 Media, Process Biochemistry, 5(7), 1187-1191 (2010).

5. Smith J. L., and Lu, S. –E. Medical Claims and Current Applications of the Potent Echinocandin Antifungals, Recent Patents on Anti-Infective Drug Discovery, 5(1), 58-63 (2010).

6. Chaney N., Wilson-Stanford S., Kastrantas J., Dahal N., Smith J. L., Rapid Method for Extracting the Antibiotic Mutacin 1140 from the Complex Fermentation Medium Yeast Extract, Canadian Journal of Microbiology, 55, 1-6 (2009).

7. Lu, S-E., Novak, J., Austin, F. W., Gu, G., Ellis, D., Kirk, M., Wilson-Stanford, S., Tonelli, M., and Smith, J. L., Occidiofungin, a Unique Antifungal Glycopeptide Produced by a strain of Burkholderia contaminans,, Biochemistry, 48(35), 8312-8321 (2009).

8. Ganyu G., Wang N., Chaney N., Smith J. L., and Lu S. -E., AmbR1 is a key transcriptional regulator for production of antifungal activity of Burkholderia contaminans strain MS14. FEMS Microbiology Letters, 297(1), 54-60 (2009).

9. Wilson-Stanford, S., Kalli, A., Hakanson, K., Kastrantas, J., Orugunty, R. S., and Smith J. L., Oxidation of Lanthionines Render the Lantibiotics Nisin and Gallidermin Inactive. Applied and Environmental Microbiology, 75(5), 1381-1387 (2009).

10. Ganyu G., Smith J. L., Wang N., Wang H., Lu S.-E., Biosynthesis of an antifungal oligopeptide in Burkholderia contaminans strain MS14. Biochemical and Biophysical Research Communications, 380, 328-332 (2009).

11. Smith J. L., and Hillman J.D., Therapeutic Potential of Type A (I) Lantibiotics, a Group of Cationic Peptide Antibiotics, Current Opinion in Microbiology, 11, 401-408. (2008).

12. Smith J. L., Hasper, Hester, Breukink, Eefjan, Novak, Jan, Cerkasov, Jeri, Hillman, Jeffrey, Wilson-Stanford, Shawanda, and Orugunty, Ravi, Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry, 47(10), 3308-3314 (2008).

13. Hasper Hester E., Kramer Naomi E., Smith J. L., Hillman J. D., Zachariah Cherian, Kuipers Oscar P., Kruijff Ben de, and Breukink Eefjan, An Alternative Mechanism of Action for Lantibiotic Peptides that Target Lipid II, Science, 313, 1636-1637 (2006).

14. Green Terry, Omjoy Ganesh, Perry Kyle, Smith J. L., Phylip Lowri H., Logan Timothy M., Hagen Stephen J., Dunn Ben M., and Edison Arthur S., IA3, an Aspartic Proteinase Inhibitor from Saccharomyces cerevisiae, Is Intrinsically Unstructured in Solution, Biochemistry, 43(14), 4071-4081 (2004).

15. Smith J. L., Zachariah Cherian, Thirumoorthy Ramanan, Rocca James, Novak, Jan, Hillman J. D., and Edison Arthur S. Structure and Dynamics of the Lantibiotic Mutacin 1140, Biochemistry, 42(35); 10372-10384 (2003).

16. Green Terry, Perry Kyle, Smith J. L., Phylip Lowri H, Logan Timothy M, Hagen Stephen J, Dunn Ben M, Edison Arthur. IA3, a yeast proteinase A inhibitor, is intrinsically unstructured in solution. Scientific World Journal. Jan 2;2(1 Suppl 2):99-101 (2002).

17. Smith J. L., Novak Jan, Rocca James, McClung Scott, Hillman J.D., and Edison Arthur S. Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics, European Journal of Biochemistry, 267, 6810-6816 (2000).

18. Evans, J. H., Smith J. L., and Keller L. R., Ion Selectivity in the Chlamydomonas reinhardtii Flagellar Regeneration System, Experimental Cell Research 230, 94-102 (1997).

Textbooks
1. Smith J. L., Orugunty, R.S. and Hillman, J.D. Lantibiotic production by Streptococcus mutans: their uses in replacement therapy for the prevention of dental caries and as antibiotics for the treatment of various infectious diseases. In: Research and Applications in Bacteriocins (M.A. Riley and O. Gillor, eds.), pp. 95-116, Horizon Bioscience, Norfolk, UK (2007).

Abstracts
1. Escano Jerome. Wilson-Stanford S, Gu G, Chen K, Lu S, Smith L, Two Structural Variants of Occidiofungin, an Antifungal Produced by Burkholderia contaminans Strain MS14, Require Two Independent Thioesterases American Society for Microbiology General Meeting, New Orleans, Louisiana, (2011).

2. Smith Leif, Ganyu Gu, Shi-En Lu, and Aixin Liu, A Genomic and Biochemical Map for the Biosynthesis of Occidiofungin, an Antifungal Produced by Burkholderia contaminans Strain MS14, American Society for Microbiology General Meeting, New Orleans, Louisiana, (2011).

3. Ellis Dayna, Smith James L., Gordon Donna, Lu Shien, Austin Frank, Initial Characterization of Occidiofungin's Activity and Toxicity, American Society for Microbiology General Meeting, San Diego CA (2010)

4. Ellis Dayna, Smith James L., Gordon Donna, Lu Shien, Austin Frank, Initial Characterization of Occidiofungin's Antifungal Activity against Candida albicans, ASM Conference on Candida and Candidiasis, Miami FL (2010)

5. Wilson-Stanford Shawanda, Ellis Dayna, and Smith James L., A Site Specific Residue in the Antibiotic Gallidermin is Modifiable Leading to the Formation of Novel and Biologically Active Variants, American Society for Microbiology General Meeting, San Francisco, CA (2010)

6. Ellis Dayna, Gordon Donna, Emrick Charles, Lu Shien, Austin Frank, Smith James L., Initial Characterization of Occidiofungin’s Target Pathway, SERYM, Little Rock AR (2010)

7. Gu Ganyu, Smith James L., Lu Shien, Genetic analysis of the genes involved in the production of occidiofungin in Burkholderia contaminans strain MS14, APS Annual Meeting, Phytopathology, Nashville,, TN (2010)

8. Gu Ganyu, Smith James L., Lu Shien, Genetic analysis of the genes involved in the production of occidiofungin in Burkholderia contaminans strain MS14, APS Annual Meeting, Phytopathology 99:S47, Portland, OR (2009)

9. Wilson-Stanford Shawanda, Ellis Dayna, Chaney Noel, Gu Ganyu, Kirk Mark, Lu Shien, Austin Frank, Novak Jan, Smith James L., Occidiofungin, a Unique Antifungal Oligopeptide Produced by Burkholderia contaminans, American Society of Microbiology General Meeting, Philadelphia PA (2009)

10. Dahal Neeti, Chaney Noel, Ellis Dayna, Smith James L., High Yield Production of the Lantibiotic Mutacin 1140 in Minimal Media, American Society of Microbiology General Meeting, Philadelphia PA (2009)

11. Smith James L., Chaney Noel, Ellis Dayna, Wilson-Stanford Shawanda, Functional Enhancement of Antimicrobials, 237th ACS National Meeting, Salt Lake City, UT (2009)

12. Wilson-Stanford Shawanda, Orugunty Ravi, Kastrantas James, Smith James, Oxidation of Lanthionines Render the Lantibiotic Gallidermin Inactive, American Society of Microbiology General Meeting, Toronto ON (2007)

13. Smith James L., Wilson-Stanford Shawanda, Breukink Eefjan, Hasper Hester, and Novak Jan, Assembly of the Lantibiotic Mutacin 1140 in Membranes, 2007 Mississippi Academy of Science (2007)

14. Smith James L., Orugunty Ravi, Pollock Jacob, Hillman J.D., Optimization of the Production and Purification of Mutacin 1140 for the Manufacture of Clinical Grade Antibiotic, American Society for Microbiology Meeting, South East Branch, St. Petersburg, Florida (2005)

15. Smith James L., Hillman J.D., “IVIAT a Novel technology that facilitates gene target discovery for the development of vaccines and diagnostics”, American Society of Microbiology, Portland, Oregon (2004)

16. Smith James L., Edison Arthur S., Hillman Jeffrey. Structural Studies of Mutacin, South Eastern Branch of the American Society for Microbiology Meeting, Gainesville, Florida (2002)

17. Smith James L., Hillman J. D., Rocca James, and Edison Arthur S. Covalent and Initial Three-Dimensional Structure of the Lantibiotic Mutacin 1140, South East Magnetic Resonance Conference, Tallahassee, Florida, p49-102, (1999)

18. Smith James L., Hillman J.D., Novak Jan, Segura Edy, Rocca James, and Edison Arthur S., Probing Structural Heterogeneity in Mutacin 1140, a Novel Lantibiotic, 40th International Experimental Nuclear Magnetic Resonance Conference, Orlando, Florida, February 28-March 5, p034-73, (1999)

19. Green Terry, Smith James L., Edison Arthur S., Perry Kyle, Zachariah Cherian, Phylip Lowri, Kay John, and Dunn Ben M., Structure-Function Studies of IA3, A Potent Inhibitor of Yeast Proteinase A, 2nd International Conference on Proteinase Inhibitors, Gainesville, Florida, December 3-6, (1999)

20. Green Terry, Smith James L., Edison Arthur S., Perry Kyle, Zachariah Cherian, Phylip Lowri, Kay John, and Dunn Ben M., Structure-Function Studies of IA3, A Potent Inhibitor of Yeast Proteinase A, 8th International Aspartic Proteinase Conference, Funchal, Maderia, Portugal, September 1-12, (1999)

21. Evans, J. H., and Smith J. L., Strontium can be Substituted for Calcium in the Chlamydomonas reinhardtii Flagellar Regeneration System, Mol. Biol. Cell 5:35a, (1994)

PATENTS

1. Hillman J. D., Orugunty R. S., and Smith J. L., Synthesis of differentially protected orthogonal lanthionines, US Utility Patent 7,521,529. Issued in April 2009.


2. Smith J. L., and Orugunty R. S., Functional Enhancement of Antimicrobials, US Utility 12/589,115, Filed 10/16/2009.


3. Lu S, Smith J. L., Austin F., and Gu Ganyu, Occidiofungin, a Unique Glycopeptide Produced by a Strain of Burkholderia contaminans, US PPA 61/217,026, (2009).


4. Smith J. L., Dahal, N., Wilson-Stanford S., Small Peptide Induction Technology, US PPA 61/273,403 (2009).